Overview

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2018-09-25
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S